Statutory Mechanics of FDAAA Section 801 and 42 CFR Part 11
Under Section 801 of the Food and Drug Administration Amendments Act of 2007 (FDAAA 801, 42 U.S.C. Section 282(j)) and the HHS/NIH Final Rule (42 CFR Part 11, effective January 2017), responsible parties conducting Applicable Clinical Trials (ACTs) of FDA-regulated drug, biologic, and device interventions must register prospective primary and secondary outcome measures within 21 days of first patient enrollment and submit structured summary clinical results no later than 12 months after the Primary Completion Date (unless a statutory certification for delayed submission pending initial FDA approval is filed).
In empirical registry audits, however, evaluating FDAAA 801 timeliness and outcome integrity requires looking upstream of the results module itself. When a sponsor fails to verify a record for more than two years after its registered completion date passed, NLM automatically transitions the study's status to UNKNOWN. Across our reconciled 2018 to 2026 Phase II/III universe, 8,352 protocols (15.22% of the entire 54,890 cohort) sit in unverified UNKNOWN status, creating an immediate blind spot for systematic reviewers and meta-analysts tracking unpublished negative trials.
| Registry Audit & Quarantine Dimension | Verified Count | FDAAA 801 & Epidemiological Audit Implication |
|---|---|---|
| Raw API v2 Phase II/III Interventional Protocols | 55,377 | Full upstream NLM extraction before temporal and outlier quarantine |
| Future or Placeholder Start Dates Excluded (>2026) | 487 | Protocols posting placeholder 2027 to 2050 start dates excluded from cohort |
Stale Unverified UNKNOWN Status Protocols |
8,352 | Unverified for 24+ months past registered completion date; masks quiet abandonments |
| Far-Future Completion Horizons (>2040 Quarantined) | 56 | Placeholder dates (up to 2050-03) defer automated primary-completion clocks |
| Anticipated vs Actual Enrollment Down-Sizing | 80.0 vs 71.0 | Cohort-wide median actual enrollment trails target sample size by 11.25% |
| Anonymized CRO Site Masking Slots (40 Sponsors) | 155,062 (16.34%) | Masks physical hospital identities behind generic "Research Site" labels |
Industry vs Academic/Federal Sponsors: Two Distinct Governance Failure Modes
Cross-tabulating consolidated biopharma corporations against major academic cancer centers and federal institutes in Table 2 exposes an asymmetric governance pattern rather than uniform compliance by either sector:
- Academic & Cooperative Group Protocols Suffer Timeline Drift, Sample Down-Sizing, and Reporting Lags: Investigator-initiated and cooperative-group Phase II studies at flagship academic institutions maintain exemplary 100.0% physical site transparency, yet experience severe sample-size shrinkage and multi-year completion extensions that routinely accompany primary outcome amendments (converting underpowered survival or clinical response endpoints into exploratory biomarker readouts). For example, NCI-sponsored trials enroll a median of
22.5actual patients against a90.0target over1,725.5median days (62.86% closed stop rate), MD Anderson sponsor-led protocols enroll24.0vs40.0target over1,707.5days (78.29% closed stop rate), and MSKCC sponsor-led protocols run1,828.5median days. - Large Biopharma Enforces Tighter FDAAA Timelines, Yet 40 Commercial Sponsors Mask Hospital Sites: Commercial registration sponsors deploy dedicated regulatory operations teams to police FDAAA Section 801 12-month results clocks and FDA Pre-NDA statistical analysis plans (SAPs), achieving much tighter completion durations (Pfizer
607days, Novo Nordisk666days, Eli Lilly691days, GSK700days). However, while Merck (99.9%), Pfizer (99.9%), Roche/Genentech (99.9%), and Eli Lilly (100.0%) name virtually every hospital site, other global sponsors obscure site-level auditability by registering anonymized CRO site codes: AstraZeneca discloses just0.9%of its facility slots (54,582masked slots), GSK discloses3.8%(15,154masked slots), Novartis discloses22.0%(20,338masked slots), and Sanofi discloses27.3%(14,134masked slots).
| Consolidated Lead Sponsor | Sector | Trials | Closed Stop % | Actual / Target N | Median Days | Site Discl. % | NDA/BLA (18-26) |
|---|---|---|---|---|---|---|---|
| AstraZeneca | Biopharma Industry | 534 | 25.2% | 181.0 / 334.0 | 782 | 0.9% | 21 |
| Novartis | Biopharma Industry | 492 | 38.0% | 119.0 / 180.0 | 1,033 | 22.0% | 29 |
| Merck & Co. | Biopharma Industry | 439 | 18.1% | 301.5 / 352.0 | 1,135 | 99.9% | 15 |
| Pfizer | Biopharma Industry | 377 | 31.2% | 241.0 / 492.0 | 607 | 99.9% | 34 |
| Roche / Genentech | Biopharma Industry | 353 | 32.5% | 185.5 / 292.5 | 1,185 | 99.9% | 19 |
| Eli Lilly and Company | Biopharma Industry | 334 | 17.0% | 312.0 / 462.5 | 691 | 100.0% | 16 |
| Sanofi | Biopharma Industry | 328 | 32.4% | 222.5 / 182.5 | 706 | 27.3% | 11 |
| GSK | Biopharma Industry | 304 | 26.1% | 284.0 / 363.0 | 700 | 3.8% | 13 |
| MD Anderson Cancer Center | Academic | 519 | 78.3% | 24.0 / 40.0 | 1,708 | 100.0% | 0 |
| National Cancer Institute (NCI) | Federal / NIH | 458 | 62.9% | 22.5 / 90.0 | 1,726 | 100.0% | 0 |
| Memorial Sloan Kettering Cancer Center | Academic | 308 | 38.9% | 24.0 / 54.0 | 1,829 | 100.0% | 0 |
| Mayo Clinic | Academic | 253 | 39.3% | 27.0 / 60.0 | 998 | 100.0% | 0 |
| Johns Hopkins University | Academic | 193 | 34.4% | 33.0 / 49.0 | 1,527 | 100.0% | 0 |
| Stanford University | Academic | 139 | 43.5% | 30.0 / 48.0 | 743 | 100.0% | 0 |
How Endpoint Amendments Interact With Enrollment Down-Sizing
When a randomized Phase II or Phase III study falls 40% to 75% short of its registered target sample size, statistical power for its original time-to-event or clinical composite primary outcome collapses unless event rates substantially exceed protocol assumptions. In clinical due diligence, a wide gap between historical EnrollmentCount (Estimated) and final EnrollmentCount (Actual) paired with repeated Primary Completion Date extensions is the strongest quantitative indicator to inspect the study's archive history on ClinicalTrials.gov for mid-study primary-to-secondary endpoint swaps or post-hoc subgroup redefinitions. FDA Notices of Noncompliance issued under FDAAA 801 and NIH grant-withholding enforcement policies have sharply increased regulatory scrutiny on overdue academic and mid-cap biotech sponsors alike, making clean registry date and outcome governance a direct prerequisite for partnership readiness.
Methodology and Audit Scope Notes
Readers can inspect exact quarantine samples (including NCT identifiers for future start dates and multi-decade completion horizons) inside the Data Provenance & Quarantine Audit tab. Note that non-U.S. single-country trials without an FDA IND or U.S. manufacturing nexus voluntarily register on ClinicalTrials.gov to satisfy ICMJE medical journal publication rules rather than statutory FDAAA 801 jurisdiction.